指南与共识消化道肿瘤与早癌消化内镜

AGA临床实践指南:Barrett食管的监测

AGA Clinical Practice Guideline on Surveillance of Barrett's Esophagus.
指南 / 共识 · Gastroenterology · 2025-01-01

美国胃肠病学会(AGA)采用GRADE框架制定Barrett食管(BE)监测指南,经证据回顾与EtD框架形成8条推荐。对非异型增生BE条件性推荐监测,柱状上皮<1 cm者条件性反对监测,强烈推荐高清白光联合染色内镜,不推荐常规使用增强采样技术或生物标志物,条件性推荐每日PPI治疗。

要点

  • 非异型增生BE患者条件性推荐内镜监测,柱状上皮<1 cm者条件性反对监测。
  • 强烈推荐高清白光内镜联合染色内镜,优于单独白光内镜。
  • 条件性推荐每日PPI治疗以预防BE进展,优于不治疗或抗反流手术。

核心结论

  • AGA基于GRADE框架制定BE监测指南,共形成8条推荐,强调高质量内镜与共享决策。

研究设计与样本

  • 指南制定机构为AGA,采用GRADE框架评估证据并形成推荐,经证据回顾与EtD框架制定。
  • 临床问题涵盖内镜监测总体作用、柱状上皮<1 cm、最佳成像、辅助采样、生物标志物、化学预防及抗反流手术。

主要发现

  • 对非异型增生BE患者条件性推荐内镜监测。
  • 对柱状上皮<1 cm患者条件性反对内镜监测。
  • 强烈推荐高清白光联合染色内镜,优于单独白光内镜。
  • 对增强采样技术(如宽区域经上皮采样)及生物标志物(p53、TissueCypher)未作推荐。
  • 条件性推荐每日PPI治疗以预防BE进展,优于不治疗或抗反流手术。

关键数值与推荐

  • 共8条推荐;非异型增生BE监测为条件性推荐;柱状上皮<1 cm反对监测为条件性推荐。
  • 高清白光联合染色内镜为强烈推荐;每日PPI治疗为条件性推荐。
  • 对增强采样技术和生物标志物未作推荐;强调高质量内镜、结构化活检和专家病理确认。
  • 指南提供监测间隔及低级别异型增生和不定型异型增生的管理指导。

临床怎么用

  • 临床应基于患者偏好进行共享决策,落实高质量内镜和结构化活检协议。
  • BE相关异型增生应由专家病理医师确认,并按指南建议确定监测间隔。
  • 对非异型增生BE可考虑条件性监测,柱状上皮<1 cm者不建议常规内镜监测。
  • 优先采用高清白光联合染色内镜,并条件性推荐每日PPI治疗预防进展。

局限性

  • 证据存在局限与缺口,指南已予强调以指导未来研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Barrett's esophagus (BE) is the only identifiable precursor to esophageal adenocarcinoma (EAC). Endoscopic surveillance has been proposed for early detection of BE-related neoplasia and reducing EAC mortality. This clinical practice guideline aims to inform clinicians and patients by providing evidence-based practice recommendations for surveillance in patients with BE. METHODS: The Grading of Recommendations Assessment, Development and Evaluation framework was used to assess evidence and make recommendations. The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients, conducted an evidence review, and used the Evidence-to-Decision Framework to develop recommendations regarding the role of endoscopic surveillance in patients with BE. The clinical domains addressed included: (1) overall role of endoscopic surveillance, (2) surveillance in patients with columnar-lined esophagus <1 cm, (3) optimal imaging modalities, (4) adjunctive sampling techniques, (5) the utility of biomarkers in risk-stratification, (6) chemopreventive strategies, and (7) antireflux procedures in the prevention of progression in patients with BE. Clinical recommendations were based on the balance between the desirable and undesirable effects, patient values, costs, and health equity considerations. RESULTS: The panel agreed on 8 recommendations. Based on the available evidence, the panel provided a conditional recommendation in favor of surveillance for patients with nondysplastic BE. In patients with columnar-lined esophagus <1 cm, a conditional recommendation was made against endoscopic surveillance. The panel made a strong recommendation in favor of a combination of high-definition white light endoscopy and chromoendoscopy compared with white light endoscopy alone. The panel made no recommendation on the use of enhanced sampling techniques, such as wide-area transepithelial sampling to enhance neoplasia detection and biomarkers such as p53 and TissueCypher to predict progression in BE. The panel provided a conditional recommendation for the use of daily proton pump inhibitor therapy compared with no therapy and compared with antireflux surgery to prevent progression in BE. CONCLUSIONS: This document provides a comprehensive outline on the role of surveillance in patients with BE. Key implementation statements included in this document stress the importance of a high-quality endoscopy examination, sampling using a structured biopsy protocol, and confirming the diagnosis of BE-related neoplasia by an expert pathologist. This document also provides guidance on surveillance intervals and management of patients with BE-related low-grade dysplasia and indefinite for dysplasia. Providers should engage in shared decision making based on patient preferences. Limitations and gaps in the evidence are highlighted to guide future research opportunities. GUIDELINE ENDORSEMENT: This guideline is endorsed by the Canadian Association of Gastroenterology.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Wani S, Zhou MJ, Sawas T, et al. AGA Clinical Practice Guideline on Surveillance of Barrett's Esophagus. Gastroenterology. 2025. PMID: 41125322. doi:10.1053/j.gastro.2025.09.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。